Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 1;2(4):e23660.
doi: 10.4161/onci.23660.

The CCL5/CCR5 Axis Promotes Metastasis in Basal Breast Cancer

Affiliations
Free PMC article

The CCL5/CCR5 Axis Promotes Metastasis in Basal Breast Cancer

Marco Velasco-Velázquez et al. Oncoimmunology. .
Free PMC article

Abstract

Recently, we have shown that the CCL5/CCR5 axis is active in patients affected by an aggressive basal subtype of breast cancer. Using preclinical models, we have demonstrated that CCR5 promotes breast cancer invasiveness and metastatic potential, while CCR5 inhibition abrogates them. Thus, CCR5 antagonists may constitute an alternative therapeutic approach for patients affected by metastatic basal breast cancer.

Keywords: CCL5; CCR5; Maraviroc; Vicriviroc; basal breast cancer; metastasis.

Figures

None
Figure 1. The CCR5 antagonist Maraviroc inhibits lung metastases in vivo. MDA-MB-231 cells expressing luciferase fused to an enhanced variant of the green-fluorescent protein (Luc2-eGFP) were injected into the tail vein of NOD/SCID mice and the bioluminescent signal was quantified weekly in vivo. Representative images of mice receiving vehicle or 8 mg/Kg Maraviroc (every 12 h) are shown in (A) Quantitative data on bioluminescence imaging (means ± SEM, n = 6) are reported in panel (B) (control mice = red line; treated mice = blue line). Statistical comparisons (*p = 0.048) were by means of Student's t-tests coupled to Welch’s correction for heterogeneous variances. (C) The presence of pulmonary tumors and the differences between experimental groups were corroborated by ex vivo imaging (left panels) and India ink staining (right panels).

Similar articles

See all similar articles

Cited by 30 articles

See all "Cited by" articles

References

    1. Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012;72:3839–50. doi: 10.1158/0008-5472.CAN-11-3917. - DOI - PubMed
    1. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle. 2010;9:4153–63. doi: 10.4161/cc.9.20.13454. - DOI - PMC - PubMed
    1. Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, et al. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 2011;18:2851–7. doi: 10.1245/s10434-011-1665-8. - DOI - PubMed
    1. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–7. doi: 10.1200/JCO.2009.25.9820. - DOI - PubMed
    1. Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, et al. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2010;54:470–6. doi: 10.1097/QAI.0b013e3181e2cba0. - DOI - PMC - PubMed

LinkOut - more resources

Feedback